#psilocybin

#psilocybin

When dosing older mice with psilocybin and comparing them to a control group, the research team found the aged mice lived 30% longer than their peers who weren't subject to the same psychedelic journey.

Psychedelic clinical trials for major depression, anxiety, PTSD, and other disorders are ongoing, with a recent positive Phase 3 trial for psilocybin in treatment-resistant depression.

Genetically engineered mice lacking IL-11 live 25% longer and healthier. Blocking IL-11 with an antibody in middle-aged mice showed similar effects. Potential for clinical therapies exists as IL-11 is present in humans.